Longidaza, vaginal and rectal suppositories 3000 me 10 pcs

Longidaza is enzymatic, proteolytic.

Pharmacodynamics

Longidaza® has hyaluronidase (enzymatic proteolytic) activity with prolonged action, chelating, antioxidant, immunomodulatory and moderately pronounced anti-inflammatory properties.

The prolongation of the enzyme’s action is achieved through its covalent binding to a physiologically active high-molecular-weight carrier (activated derivative of N-oxide poly-1,4-ethylenpiperazine, analog of polyoxidonium) which has its own pharmacological activity. Longidaza® shows antifibrotic properties, weakens acute phase of inflammation, regulates (increases or decreases depending on the initial level) synthesis of inflammatory mediators (IL-1 and tumor necrosis factor-alpha), increases humoral immune response and resistance of the body to infection.

The pronounced antifibrotic properties of Longidaza® are provided by conjugation of hyaluronidase with the carrier, which significantly increases resistance of the enzyme to denaturing influences and to the action of inhibitors: the enzymatic activity of Longidase® is preserved when heated to 37°C for 20 days, while the native hyaluronidase in the same conditions loses its activity within a day. Longidaza® provides simultaneous local presence of the proteolytic enzyme hyaluronidase and a carrier, which can bind the enzyme inhibitors and stimulators of collagen synthesis (iron ions, copper ions, heparin, etc.) released during hydrolysis of matrix components. Due to these properties Longidase® has not only the ability to depolymerize the matrix of connective tissue in fibrotic-granulematous formations, but also suppresses the reverse regulatory reaction directed to the synthesis of components of connective tissue.

The specific substrate of testicular hyaluronidase is glycosaminoglycans (hyaluronic acid, chondroitin, chondroitin-4-sulfate, chondroitin-6-sulfate), which form the basis of the connective tissue matrix. As a result of depolymerization (breaking the bond between C1acetylglucosamine and C4 glucuronic or induronic acids) glycosaminoglycans change their basic properties: viscosity is reduced, the ability to bind water, metal ions is reduced, the permeability of tissue barriers is temporarily increased, the movement of fluid in the intercellular space is facilitated, the elasticity of connective tissue increases, which is manifested in a reduction of tissue swelling, flattening of scars, increased joint movement volume, reduction of contractures and prevention of their formation, reduction of adhesions.

Biochemical, immunological, histological and electron-microscopic investigations prove that Longidaza® does not damage the normal connective tissue, but causes destruction of the connective tissue altered in composition and structure in the area of fibrosis.

Longidaza® has no mutagenic, embryotoxic, teratogenic and carcinogenic effect.

The drug is well tolerated by patients, no local and general allergic reactions were noted.

The use of Longidaza® in therapeutic doses during or after surgical treatment does not cause deterioration of the course of postoperative period or progression of the infection; it does not slow down the recovery of bone tissue.

Indications

Active ingredient

Composition

1suppository contains:

Active ingredient:

Hyaluronidase conjugate with oxide copolymer,

1,4-ethylenpiperazine and (N-carboxymethyl) 1,4-ethylenpiperazine bromide 3000 IU;

Auxiliary substance:

Cocoa butter – to obtain a suppository weight of 1.3 g.

How to take, the dosage

Rectally, 1 suppository once a day after cleansing the bowels.

Vaginally, once daily (at night) 1 suppository is inserted into the vagina in a supine position.

Longidaza® suppositories 3000 ME are recommended for a course of 10 to 20 injections.

The regimen of administration is adjusted depending on the severity, stage and duration of the disease: Longidaza® is administered every other day or at 2-3 day intervals.

Recommended regimens and doses:

If necessary, it is recommended to repeat the course of Longidase® not earlier than in 3 months or long-term supporting therapy – 1 suppository once in 5-7 days during 3-4 months.

Interaction

In the use of Longidase in patients receiving salicylates, cortisone, ACTH, estrogens or antihistamines in high doses may reduce the effectiveness of the enzyme hyaluronidase.

When prescribing in combination with other medicinal products the possibility of increasing their absorption (bioavailability) and enhancing the systemic action should be taken into account.

Special Instructions

When used against the background of acute foci of infection to prevent the spread of infection, prescribe under the cover of antimicrobial agents.

In case of allergic reactions the use of Longidase should be stopped immediately.

Longidase has no mutagenic and carcinogenic effects.

With caution and no more than once weekly use in patients with renal impairment.

Contraindications

With caution (use no more than once a week): renal failure; history of pulmonary bleeding.

Side effects

Rarely – allergic reactions in case of hypersensitivity.

Pregnancy use

The drug is contraindicated in pregnancy.

There are no data on the safety of the drug during lactation.

Longidase has no embryotoxic and teratogenic effects.